B-cell-depleting therapy in systemic lupus erythematosus
M Ramos-Casals, I Sanz, X Bosch, JH Stone… - The American journal of …, 2012 - Elsevier
The emergence of a new class of agents (B-cell-depleting therapies) has opened a new era
in the therapeutic approach to systemic lupus erythematosus, with belimumab being the first
drug licensed for use in systemic lupus erythematosus in more than 50 years. Four agents
deserve specific mention: rituximab, ocrelizumab, epratuzumab, and belimumab. Controlled
trials have shown negative results for rituximab, promising results for epratuzumab, and
positive results for belimumab. Despite these negative results, rituximab is the most-used …
in the therapeutic approach to systemic lupus erythematosus, with belimumab being the first
drug licensed for use in systemic lupus erythematosus in more than 50 years. Four agents
deserve specific mention: rituximab, ocrelizumab, epratuzumab, and belimumab. Controlled
trials have shown negative results for rituximab, promising results for epratuzumab, and
positive results for belimumab. Despite these negative results, rituximab is the most-used …
